Apaxen is a privately-held biotechnology company developing innovative treatments for patients with diseases that depend on chronic NLRP3 Inflammasome activation. Our primary focus is on treatment of pulmonary arterial hypertension (PAH)
We develop first-in-class small molecule inhibitors of NLRP3 Inflammasome activation, a key driver of inflammation in many diseases. Our drugs work by neutralizing Macrophage Migration Inhibitory Factor (MIF), a protein which is required for the construction and activation of NLRP3 Inflammasomes.
Apaxen’s lead compound, MFC-1040 is being developed as a “disease modifying” treatment of pulmonary arterial hypertension (PAH), a rare and fatal inflammatory disease, with a strong medical need since approved treatments are symptomatic vasodilators and associated with low median survival.
Our approach is a platform for the discovery and development of a pipeline of MIF/Inflammasome inhibitors for treatment of many inflammatory and autoimmune diseases, inflammaging related diseases and cancer.
Apaxen has its headquarters in Gosselies (Belgium), at the Biopark Charleroi Brussels South.